Human Health and Exposure Monitoring Teams

The LRI Health Effects Monitoring Team (HEMT) oversees LRI programme development and progress in funded research on chemical carcinogenicity, chemical allergy, neurodevelopmental disorders in children, the development of alternative approaches in mammalian toxicity testing, and new areas like epigenetics and human health effects of nanomaterials.

The current 2020 research portfolio under the health and exposure programme looks as follows*:

  • AIMT 5.2: A computational model for neural tube closure, based on the dedicated developmental ontology constructed in the LRI AIMT-5 project, for in silico predictive toxicology of neural tube defects  Principal investigator: Prof. Dr. Aldert Piersma, RIVM, National Institute for Public Health and the Environment, The Netherlands
  • B 12.3: Assessing the relevance of the dust contribution in consumer exposure to substances from consumer products and articles (DustEx)                                                                                                              Principal investigator: Dr. John Little, Virginia Tech, USA
  • B 15.3: ECEL v3.0: Technical improvements and population of the integrated risk management measure (RMM) library
    Principal investigator: Dr. Wouter Fransman, Netherlands Organisation for Applied Scientific Research (TNO), The Netherlands
  • B 19.2: Refinement of a framework for extrapolating of worker exposure measurement data
    Principal Investigator: Dr. Wouter Fransman, Netherlands Organisation for Applied Scientific Research (TNO), The Netherlands
  • B 21: In Vitro Data To Parameterise PBPK Models For Inhalation Exposure
    Principal investigator: Katharina Schwarz, Fraunhofer ITEM, Germany
  • B 22: Tiered Methods for Quantifying Exposure to Complex Substances (“TMEx-Complex”)
    Principal investigator: Mark Parnis, Trent University, CA
  • B 23: Optimizing the benefit of REACH worker exposure assessments: ensuring meaningful health risk communication
    Principal investigator: Wouter Fransman, TNO, NL
  • C 4: Towards the Development of an Omics Data Analysis Framework (ODAF) for Regulatory Application.
    Principal investigator: Dr. Florian Caiment, Maastricht University, The Netherlands
  • C 5: Integrating Multiple Molecular-level Data Streams to understand (a) range of normal adaptation vs pathology and (b) molecular generated gene expression changes and persistence over time.
    Principal investigator: Dr. Jörg Hackermüller, Helmholtz Centre for Environmental Research (UFZ), Germany
  • C 6: Toxicogenomic Approaches to Support Read-Across
    Principal investigator: George Daston, Procter & Gamble, USA
  • C 7: ELUMICA – Elucidating Microbial Metabolic Capacity
    Principal investigator: Saskia Sperber, BASF SE, Germany
  • C 8: MATCHING – MetAbolomics ring-Trial for CHemical groupING
    Principal investigator: Mark Viant, University of Birmingham, UK
  • EMSG 59: In Vitro Data To Parameterise PBPK Models For Inhalation Exposure
    Principal investigator: Aldert Piersma, RIVM, The Netherlands
  • EMSG 60: Incidence trends of selected endocrine-related diseases and conditions in Europe and North America, and the contribution of changes in human reproduction
    Principal investigator: Eva Negri, Università degli Studi di Milano, IT